Megarozet Tab.

Ingredient

Ezetimibe/Rosuvastatin Calcium

Content

10/5mg, 10/10mg, 10/20mg

Indication

Treatment of primary hypercholesterolemia: As an adjunct to diet for the reduction of elevated total-C, LDL-C, apolipoprotein-B (apo-B), triglycerides, and non-high-density lipoprotein cholesterol (HDL-C), and to increase HDL-C in patients with primary (heterozygous familial and nonfamilial) hyperlipidemia or mixed hypercholesterolemia

Menactra®

Ingredient

0.5-milliliter (mL) dose of MenQuadfi® to contain 10 µg each of meningococcal A, C, W, and Y polysaccharides conjugated to approximately 55 µg of tetanus toxoid protein carrier

Content

Indication

r active immunization to prevent invasive meningococcal
disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Menactra
is approved for use in individuals 9 months through 55 years of age

Minjuvi™ Inj. 200mg

Ingredient

One vial of powder contains 200 mg of tafasitamab

Content

White to slightly yellowish lyophilised powder.

Indication

In combination with lenalidomide followed by MINJUVI monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).

Munobal Tab.

Ingredient

Felodipine

Content

2.5mg, 5mg

Indication

Treatment of hypertension, stable angina pectoris.

Olmediqual^®

Ingredient

Olmesattan / Amlodipine

Content

5/20mg 5/40mg 10/40mg

Indication

Treatment of essential hypertension.

Sevikar is indicated in adult patients whose blood pressure is not adequately controlled on olmesartan medoxomil or amlodipine monotherapy

Olmediqual^®HCT

Ingredient

Olmesattan / Amlodipine / HCTZ

Content

5/20/12.5mg 5.40/12.5mg 10/40/12.5mg

Indication

Treatment of essential hypertension.

Add-on therapy

Sevikar HCT is indicated in adult patients whose blood pressure is not adequately controlled on the combination of olmesartan medoxomil and amlodipine taken as dual-component formulation.

Ovestin Vaginal Suppositories

Ingredient

Estriol　

Content

0.5mg

Indication

Vulvovaginal diseases and symptoms due to estrogen deficiency after menopause and postmenopausal period or oophorectomy: atrophic vaginitis, vulvar itching, dyspareunia

Paxerontine SR Tab. 12.5mg

Ingredient

Paroxetine Hydrochloride

Content

12.5mg

Indication

1) Treatment of major depressive disorder
2) Treatment of panic disorder, with or without agoraphobia
3) Treatment of social anxiety disorder, also known as social phobia
4) Treatment of premenstrual dysphoric disorder (PMDD)

Paxerontine SR Tab. 25mg

Ingredient

Paroxetine Hydrochloride

Content

25mg

Indication

1) Treatment of major depressive disorder
2) Treatment of panic disorder, with or without agoraphobia.
3) Treatment of social anxiety disorder, also known as social phobia.
4) Treatment of premenstrual dysphoric disorder (PMDD).

Pemzayre® tablet 13.5mg

Ingredient

1 Tab(240.0mg) contains, pemigatinib (In-house spec.) 13.5mg

Content

White to off-white round tablet, one side debossed with “I”, the other side with “13.5”.

Indication

The treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after one or more prior line of systemic therapy.